{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:45:05Z","timestamp":1791402305031,"version":"4.3.3"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,12,18]],"date-time":"2003-12-18T00:00:00Z","timestamp":1071705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2004,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The optimal antifungal prophylactic regimen for patients with acute myelogenous leukemia (AML) or high\u2010risk myelodysplastic syndrome (MDS) undergoing induction chemotherapy has yet to be identified. A prospective historical control study evaluated the efficacy and safety of amphotericin B lipid complex (ABLC) in this patient population.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Newly diagnosed patients with AML or high\u2010risk MDS who were undergoing induction chemotherapy received prophylactic ABLC 2.5 mg\/kg intravenously 3 times weekly. This treatment group was compared with a historical control group that had similar baseline characteristics and received prophylactic liposomal amphotericin B (L\u2010AmB) 3 mg\/kg 3 times weekly. The primary endpoint was the incidence of documented or suspected fungal infections during and up to 4 weeks after cessation of prophylaxis. Reported adverse events were used to assess tolerability.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The overall efficacy of antifungal prophylaxis was similar in patients who received ABLC and patients who received L\u2010AmB (<jats:italic>P<\/jats:italic> = 0.95). Among 131 ABLC\u2010treated patients and 70 L\u2010AmB\u2010treated patients who ere assessed for efficacy and safety, 49% of patients in each group completed therapy without developing a documented or suspected fungal infection. Documented fungal infections occurred in 5% of ABLC\u2010treated patients and in 4% of L\u2010AmB\u2010treated patients. Alternative antifungal strategies were required because of persistent fever or pneumonia of unknown pathogen in 28% and 32% of ABLC\u2010treated and L\u2010AmB\u2010treated patients, respectively. Grade 3 and 4 adverse events, therapy discontinuations due to adverse events, and survival rates also were similar between treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>ABLC and L\u2010AmB appeared to have similar efficacy and were tolerated well as antifungal prophylaxis in patients with AML and high\u2010risk MDS who were undergoing induction chemotherapy. Cancer 2004. \u00a9 2003 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11936","type":"journal-article","created":{"date-parts":[[2004,1,22]],"date-time":"2004-01-22T04:00:50Z","timestamp":1074744050000},"page":"581-589","source":"Crossref","is-referenced-by-count":35,"title":["Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy"],"prefix":"10.1002","volume":"100","author":[{"given":"Gloria N.","family":"Mattiuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kontoyiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaam","family":"Raad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebiyou","family":"Bekele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elihu","family":"Estey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,1,20]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00159-X"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10610"},{"key":"e_1_2_5_4_2","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood.V86.6.2063.bloodjournal8662063","article-title":"Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal","volume":"86","author":"Uzun O","year":"1995","journal-title":"Blood"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401137"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000007301"},{"key":"e_1_2_5_7_2","first-page":"332a","article-title":"Intravenous itraconzole (ITRA) versus caspofungin (CASPO) for prophylaxis of invasive fungal infections (IFI) in patients (PTS) with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC)","volume":"100","author":"Mattiuzzi GN","year":"2002","journal-title":"Blood"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<291::AID-CNCR13>3.0.CO;2-O"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940415)73:8<2099::AID-CNCR2820730814>3.0.CO;2-N"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-11-199406010-00003"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-7-199304010-00003"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11094"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1887-1893.2000"},{"key":"e_1_2_5_14_2","first-page":"193","article-title":"Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy","volume":"25","author":"Takatsuka H","year":"1999","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.4.1035"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/515129"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309067926"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.52.5.376"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701543"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402495"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109097650"},{"key":"e_1_2_5_22_2","volume-title":"ABELCET\u00ae [package insert]","author":"Enzon Pharmaceuticals","year":"2002"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/323335"},{"key":"e_1_2_5_24_2","unstructured":"National Cancer Institute. NCI common toxicity criteria\u2014Version 1 [monograph online]. Available from URL:http:\/\/www.accessdata.fda.gov\/scripts\/cder\/onctools\/toxicity.cfm[accessed April 15 2003]."},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780140404"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.5.891"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90345-X"},{"key":"e_1_2_5_28_2","first-page":"577","article-title":"Randomized double\u2010blind study of liposomal amphotericin B (Ambisome) prophylaxis in invasive fungal infections in bone marrow transplant recipients","volume":"12","author":"Tollemar J","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/516353"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/377210"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.1.85"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.1032-1037.2002"},{"key":"e_1_2_5_33_2","first-page":"573","article-title":"In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species","volume":"17","author":"Clancy CJ","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019048-199803000-00003"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/317451"},{"key":"e_1_2_5_36_2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","article-title":"Lipid formulations of amphotericin B: clinical efficacy and toxicities","volume":"27","author":"Wong\u2010Berringer A","year":"1998","journal-title":"Clin Infect Dis"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11936","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:39:57Z","timestamp":1760276397000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,20]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["10.1002\/cncr.11936"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11936","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,20]]}}}